News | Breast Imaging | May 26, 2020

High-resolution 3-D View Inside Breast Tumors

Opto-acoustic mesoscopy visualizes tumor tissue patterns

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

Maximum intensity projections from each frequency band are shown separately in the xz plane (d, e) and in the xy plane (g, h). f and i Merged images are shown in the right column. Scale bars, 1 mm

Maximum intensity projections from each frequency band are shown separately in the xz plane (de) and in the xy plane (gh). f and i Merged images are shown in the right column. Scale bars, 1 mm

May 26, 2020 — Breast cancer is the most common cancer in women. But individual tumors can vary significantly, presenting different spatial patterns within their mass. Researchers at the Technical University of Munich (TUM) and Helmholtz Zentrum München have now succeeded in visualizing spatial changes within tumors by means of optoacoustics. This method may be helpful for the future development of new drugs.

Malignant tumors consume nutrients and oxygen faster than healthy cells. To do so, they recruit blood vessels in their environment. Depending on tumor type and genetic profile, there are differences on how tumors look internally. Typically, tumors present different patterns across their volume. The role of this spatial heterogeneity is not well understood or studied in living tumors. Typically used to understand biological functions in tumors, optical microscopy, for example, gives limited insights into the spatial heterogeneity of tumors as it only accesses volumes of less than a cubic millimeter.

High resolution with new imaging method

A new technique developed by Munich researchers, known as multi-spectral optoacoustic mesoscopy (MSOM), has now been shown capable of resolving optical contrast through tumor volumes that are at least 1,000 times larger than those possible with optical microscopy, enabling high-resolution visualization of tumor heterogeneity patterns. With this imaging method, the tumor is first excited from all sides with pulses of infrared laser light. “Tumor and tissue components that absorb this excitation light undergo a tiny, transient temperature increase, which leads to a small local volume expansion, followed by a contraction. This expansion and contraction process generates a weak ultrasound signal, which we collect with a detector,” said guest researcher Jiao Li, M.D.

The data collected is mathematically processed to form light absorption images which indicate different tumor patterns reflecting tumor oxygenation and vascularization. “For the first time, MSOM offers optical images that reach inside tumors to depths of ten millimeters and more with a resolution of less than 50 micrometers,” said Li.

Understanding functional variety in tumors

“MSOM imaging of solid tumors allowed us to see tumors in a new light,” said Prof. Vasilis Ntziachristos, holder of the Chair of Biological Imaging at TUM and Director of the Institute for Biological and Medical Imaging at Helmholtz Zentrum München. “MSOM allows us to understand how tumor functionality varies across the tumor, clearly moving the reach of optical observations well beyond the depth penetration limitations of optical microscopy.”

In the pictures taken from mamma carcinomas of mice, researchers can see patterns indicating the presence or absence of blood vessels, and thus study blood supply patterns. MSOM can also resolve hemoglobin levels, and indicate whether oxygen is bound to hemoglobin or not. Furthermore, MSOM images were used to determine permeability of the vessel walls relative to nanoparticles. Using the mouse model, the scientists were already able to track how tiny gold particles were transported.

3-D tumor pictures without surgical biopsy

In contrast to conventional histology, where tissue has to be removed, cut up and examined under the microscope by a pathologist, MSOM allows a three-dimensional analysis of entire living tumors without the need for surgical biopsies. This further supports longitudinal studies so that tumor growth or recession under different drugs can be studied with greater accuracy. All of which paves the way for an improved understanding of biological function and drug efficacy during drug development for humans.

For more information: www.tum.de/

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...